Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie’s Mavyret Shows Sky-High Hep C Cure Rates

Chicago-based AbbVie announced new data for Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.

Read More »

Merck drug Keytruda succeeds in late-stage esophageal cancer trial

Merck & Co.’s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract.

Read More »

As Deadliest Strain Ravages Country, Four Experimental Ebola Vaccines to Be Deployed in the Congo

As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials took four experimental vaccines to the front lines and began to administer it to patients who may have been exposed to the deadly virus.

Read More »

Amarin Plans to Seek FDA Approval for CV Indication for Fish Oil Drug

Clinical data for a fish-oil-based drug from Amarin Corporation confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.

Read More »

AstraZeneca’s Farxiga curbs heart failure, kidney risks

The largest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca’s Farxiga can prevent heart failure and cut the risk of kidney problems in a broad range of patients.

Read More »

Lilly scraps a BACE program for Alzheimer’s

Eli Lilly scrapped a Phase II clinical trial for N3pG, a humanized IgG1 monoclonal antibody, plus BACE in the treatment of Alzheimer’s.

Read More »

Endo targets 2020 for launch of cellulite treatment

Endo International Plc expects to launch the company’s treatment for cellulite in the second half of 2020, a day after announcing results from two late-stage trials testing the drug.

Read More »

Foamix’s treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals’ experimental foam treatment FMX103 for rosacea met the main goals of two late-stage studies.

Read More »

Aveo’s RCC Drug Hits Mark in Phase III Trial

Aveo Oncology’s Phase III study of tivozanib for highly refractory advanced or metastatic renal cell carcinoma (RCC) met the primary endpoint of demonstrating a statistically significant benefit in PFS.

Read More »

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

AbbVie, Roche combo treatment meets main goal of leukemia trial

AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.

Read More »

Long-lasting HIV injection is a step closer after second GSK study

A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients.

Read More »

Darzalex Dazzles in Multiple Myeloma Late-Stage Trial

Denmark-based Genmab released top-line data from the Phase III MAIA clinical trial of Darzalex (daratumumab), a drug licensed to Johnson & Johnson’s Janssen.

Read More »

Lundbeck Schizophrenia Drug Fails Phase III Study

Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.

Read More »

Ultragenyx Plunges With Phase III Trial Failure

Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.

Read More »

Bayer, Orion drug delays spread of prostate cancer

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Read More »

Pfizer and Lilly non-opioid drug helps reduce osteoarthritis pain

Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

Read More »

AbbVie RA drug succeeds in late-stage trial

Upadacitinib, in development for rheumatoid arthritis (RA), showed significant improvement in physical function, pain and quality of life versus the commonly prescribed generic methotrexate.

Read More »

Biogen, UCB’s Lupus Treatment Fails Phase II Study

Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.

Read More »

ESMO 2018: BMS’ Opdivo Shines in RCC Results

An Opdivo-Yervoy combo yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma than standard of care sunitinib.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom